Find Reports

Select Report Type

Reimbursement Review

Displaying 251 - 275 of 1426

Please scroll or swipe to the right to view the full content.

Title	Brand Name	Generic Name	Files	Therapeutic Area	Recommendation Type	Status	Submission Date	Recommendation Date Sort ascending	Project Number
Renal Cell Carcinoma (RCC)			Final Report	Renal Cell Carcinoma (RCC)		Complete		Sep 6, 2022	PH0013-000
atezolizumab	Tecentriq	atezolizumab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Small Cell Lung Cancer	Reimburse with clinical criteria and/or conditions	Complete	Jan 24, 2022	Sep 1, 2022	PC0277-000
atezolizumab	Tecentriq	atezolizumab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Non-small cell lung cancer	Reimburse with clinical criteria and/or conditions	Complete	Feb 24, 2022	Sep 1, 2022	PC0269-000
pembrolizumab	Keytruda	pembrolizumab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Triple-negative breast cancer	Reimburse with clinical criteria and/or conditions	Complete	Feb 17, 2022	Aug 31, 2022	PC0279-000
tepotinib	Tepmetko	tepotinib	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Locally advanced or metastatic non-small cell lung cancer	Do not reimburse	Complete	Aug 30, 2021	Aug 24, 2022	PC0255-000
dostarlimab	Jemperli	dostarlimab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Endometrial cancer	Do not reimburse	Complete	Oct 7, 2021	Aug 24, 2022	PC0263-000
abrocitinib	Cibinqo	abrocitinib	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder Feedback on Draft Recommendation	Atopic dermatitis, moderate to severe	Reimburse with clinical criteria and/or conditions	Complete	Apr 26, 2021	Aug 19, 2022	SR0686-000
faricimab	Vabysmo	faricimab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Macular degeneration, age-related	Reimburse with clinical criteria and/or conditions	Complete	Jan 31, 2022	Aug 12, 2022	SR0719-000
mogamulizumab	Poteligeo	mogamulizumab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	mycosis fungoides (MF), Sézary syndrome (SS)	Reimburse with clinical criteria and/or conditions	Complete	Sep 13, 2021	Aug 12, 2022	PC0244-000
nusinersen	Spinraza	nusinersen	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input combined Report Stakeholder Feedback on Draft Recommendation	Spinal Muscular Atrophy	Do not reimburse	Complete	Dec 2, 2021	Aug 11, 2022	SR0713-000
asciminib	Scemblix	asciminib	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Philadelphia chromosome-positive chronic myeloid leukemia	Reimburse with clinical criteria and/or conditions	Complete	Jan 20, 2022	Aug 5, 2022	PC0275-000
NSCLC without actionable oncog...			Final Report	Unmutated Non-small cell lung cancer		Complete		Aug 5, 2022	PH0012-000
selinexor	Xpovio	selinexor	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Multiple myeloma	Reimburse with clinical criteria and/or conditions	Complete	Jan 14, 2022	Jul 29, 2022	PC0276-000
zanubrutinib	Brukinsa	zanubrutinib	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Mantle cell lymphoma (MCL)	Do not reimburse	Complete	Sep 30, 2021	Jul 27, 2022	PC0267-000
sodium phenylbutyrate and urso...	Albrioza	sodium phenylbutyrate and ursodoxicoltaurine	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Amyotrophic lateral sclerosis (ALS)	Reimburse with clinical criteria and/or conditions	Complete	Nov 24, 2021	Jul 21, 2022	SR0711-000
ruxolitinib	Jakavi	ruxolitinib	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Graft versus host disease	Reimburse with clinical criteria and/or conditions	Complete	Aug 10, 2021	Jul 15, 2022	SR0706-000
avalglucosidase alfa	Nexviazyme	avalglucosidase alfa	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder Feedback on Draft Recommendation	Pompe disease	Reimburse with clinical criteria and/or conditions	Complete	Sep 30, 2021	Jul 5, 2022	SR0703-000
lisocabtagene maraleucel	Breyanzi	lisocabtagene maraleucel	Recommendation and Reasons Clinical, Pharmacoeconomic, Ethics, and Stakeholder Input Combined Report Stakeholder feedback on Draft Recommendation	Relapsed or refractory large B-cell lymphoma	Reimburse with clinical criteria and/or conditions	Complete	Aug 9, 2021	Jun 29, 2022	PG0258-000
selpercatinib	Retevmo	selpercatinib	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder Feedback on Draft Recommendation	Thyroid cancer	Reimburse with clinical criteria and/or conditions	Complete	Oct 29, 2021	Jun 29, 2022	PC0274-000
lenvatinib and pembrolizumab	Lenvima and Keytruda	lenvatinib and pembrolizumab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	advanced or metastatic renal cell carcinoma	Reimburse with clinical criteria and/or conditions	Complete	Nov 15, 2021	Jun 23, 2022	PC0268-000
cenegermin	Oxervate	cenegermin	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder Feedback on Draft Recommendation	Neurotrophic keratitis	Reimburse with clinical criteria and/or conditions	Complete	Oct 29, 2021	Jun 23, 2022	SR0704-000
Human Epidermal Growth Factor ...			Final Report	Esophageal or Gastroesophageal Junction Cancer		Complete		Jun 21, 2022	PH0010-000
tafamidis	Vyndaqel	tafamidis	Recommendation and Reasons Request for Advice Report Stakeholder feedback on Draft Recommendation	Transthyretin-mediated amyloidosis	Reimburse with clinical criteria and/or conditions	Complete	Dec 14, 2021	Jun 17, 2022	SF0722-000
elexacaftor/tezacaftor/ivacaft...	Trikafta	elexacaftor/tezacaftor/ivacaftor and ivacaftor	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder Feedback on Draft Recommendation	Cystic fibrosis, F508del CFTR mutation, 6 years and older	Reimburse with clinical criteria and/or conditions	Complete	Nov 5, 2021	Jun 17, 2022	SR0710-000
amifampridine phosphate	Firdapse	amifampridine phosphate	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Lambert-Eaton Myasthenic Syndrome, adults	Reimburse with clinical criteria and/or conditions	Complete	Nov 15, 2021	Jun 16, 2022	SR0664-000

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 251 - 275 of 602

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Sub Line	Status	Project Number
Virtual Care Use in Primary Care or Specialty Care Settings	Virtual Care Use in Primary Care or Specialty Care Settings In-Brief Guidelines for use of virtual care in primary care or specialty care s…	Aug 17, 2022	Rapid Review	Completed	RC1444-000
Concurrent or Sequential Administration of Drugs for COVID-19 and Influenza	Concurrent or Sequential Administration of Drugs for COVID-19 and Influenza	Aug 15, 2022	Rapid Review	Completed	RC1446-000
Liposuction for Lipedema: A 2022 Update	Liposuction for Lipedema: 2022 Update	Aug 12, 2022	Rapid Review	Completed	RC1447-000
Mesalamine for the Treatment of Crohn Disease	Mesalamine for the Treatment of Crohn’s Disease	Aug 10, 2022	Rapid Review	Completed	RC1445-000
Post-COVID-19 Condition: A summary of existing guidelines	Post-COVID-19 Condition: A summary of existing guidelines	Aug 4, 2022	Technology Review	Complete	HC0037-000
Portable Bone Imaging Devices for Screening and Diagnosing Osteoporosis	Portable Bone Imaging Devices for Screening and Diagnosing Osteoporosis	Aug 2, 2022	Rapid Review	Completed	RC1438-000
Models of Care for People Re-Entering the Community After Incarceration	Models of Care for People Re-Entering the Community After Incarceration	Aug 2, 2022	Technology Review	Completed	HC0039-000
Low-Dose Ipilimumab in Combination With Nivolumab or Pembrolizumab for the Treatment of Advanced Melanoma	Low-Dose Ipilimumab in Combination With Nivolumab or Pembrolizumab for the Trea…	Aug 2, 2022	Rapid Review	Completed	RC1441-000
Interventions for the treatment of obstructive sleep apnea: economic update		Jul 29, 2022	Technology Review	In Progress	HE0038-000
Guanfacine for Autism Spectrum Disorder, Attention-Deficit/Hyperactivity Disorder, and/or Oppositional Defiance Disorder	Guanfacine for Autism Spectrum Disorder, Attention-Deficit/Hyperactivity Disord…	Jul 27, 2022	Rapid Review	Completed	RC1440-000
Multiple Prosthetic Sockets for Lower Limb Amputations	Multiple Prosthetic Sockets for Lower Limb Amputations	Jul 21, 2022	Rapid Review	Completed	RC1439-000
Improving Access to Primary Care in Canada	Improving Access to Primary Care in Canada	Jul 19, 2022	Environmental Scan	Completed	ES0363-000
Diacetylmorphine for Adults With Opioid Dependence	Diacetylmorphine for Adults With Opioid Dependence	Jul 18, 2022	Rapid Review	Completed	RC1437-000
Vandetanib for Medullary Thyroid Cancer	Vandetanib for Medullary Thyroid Cancer	Jul 13, 2022	Technology Review	Completed	HD0009-000
Tecovirimat for the Treatment of Human Monkeypox	HC0040-Tecovirimat-(Tpoxx)-Update-sep28.pdf HC0040-Tecovirimat-Drug-Implementation-Advice-Report.pdf	Jul 12, 2022	Technology Review	Completed	HC0040-000
Syphilis Screening for Adolescents and Adults	Syphilis Screening for Adolescents and Adults	Jul 12, 2022	Rapid Review	Completed	RC1434-000
Surveillance Colonoscopy Following Surgery for Colon Cancer	Surveillance Colonoscopy Following Surgery for Colon Cancer	Jul 7, 2022	Summary of Abstracts	Completed	RB1623-000
Intermittently Scanned and Real-Time Continuous Glucose Monitoring for People With Diabetes	Intermittently Scanned and Real-Time Continuous Glucose Monitoring for People W…	Jul 6, 2022	Rapid Review	Completed	RC1436-000
Infliximab for Graft versus Host Disease	Infliximab for Graft versus Host Disease	Jul 6, 2022	Summary of Abstracts	Completed	RB1621-000
Assessment of Postoperative Vital Signs Frequency	Assessment of Postoperative Vital Signs Frequency	Jun 27, 2022	Summary of Abstracts	Completed	RB1620-000
Removable Rigid Dressings for the Post-Operative Management of Leg Amputations	Removable Rigid Dressings for the Post-Operative Management of Leg Amputations	Jun 27, 2022	Summary with Critical Appraisal	Completed	RC1432-000
Private IV Infusion Clinics in Canada	Private IV Infusion Clinics in Canada	Jun 24, 2022	Environmental Scan	Completed	ES0365-000
Intranasal Glucagon for the Treatment of Hypoglycemia	Intranasal Glucagon for the Treatment of Hypoglycemia	Jun 24, 2022	Summary with Critical Appraisal	Completed	RC1435-000
Ibrutinib for Chronic Graft versus Host Disease	Ibrutinib for Chronic Graft versus Host Disease	Jun 24, 2022	Summary with Critical Appraisal	Completed	RC1433-000
Formulary Management of Targeted Immune Modulators for Ulcerative Colitis		Jun 24, 2022	Technology Review	In Progress	HD0010-000

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 110 of 110

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 27 of 27

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 251 - 275 of 2138

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
inclisiran	Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group Input	Dec 20, 2024	Reimbursement Review		Complete	SR0791-000
Brentuximab vedotin	Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group Input	Dec 17, 2024	Reimbursement Review		Complete	PC0371-000
Antiviral Drugs for the Treatment of Suspected or Confirmed Influenza A or Influenza B		Dec 16, 2024	Health Technology Review	Systematic Review	In Progress	RE0052-000
Icatibant Implementation Advice Panel	Implementation Advice for Icatibant	Dec 16, 2024	Health Technology Review	Technology Review	Completed	HC0097-000 - SX0849-000
donanemab	Patient and Clinician Group input	Dec 16, 2024	Reimbursement Review		Suspended	SR0857-000
lecanemab	Patient and Clinician Group input	Dec 16, 2024	Reimbursement Review		Suspended	SR0822-000
atogepant	Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group input	Dec 16, 2024	Reimbursement Review		Complete	SR0817-000
Emerging Antiviral Drugs to Prevent or Treat Influenza	Emerging Antiviral Drugs to Prevent or Treat Influenza	Dec 16, 2024	Horizon Scan	Emerging Health Technologies	Completed	EH0128-000
belumosudil	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Dec 13, 2024	Reimbursement Review		Complete	SR0789-000
Philadelphia negative acute lymphoblastic leukemia	Proposed Scope	Dec 12, 2024	Reimbursement Review	Provisional Funding Algorithm	Active	PH0067-000
Non-small-cell lung cancer	Proposed Scope Proposed Scope # PH0059-000	Dec 12, 2024	Reimbursement Review	Provisional Funding Algorithm	Active	PH0065-000
vutrisiran	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Dec 12, 2024	Reimbursement Review		Complete	SR0801-000
somapacitan	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Dec 12, 2024	Reimbursement Review		Complete	SR0779-000
dupilumab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Dec 12, 2024	Reimbursement Review		Complete	SR0774-000
roflumilast	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Dec 12, 2024	Reimbursement Review		Complete	SR0771-000
cenobamate	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Dec 12, 2024	Reimbursement Review		Complete	SR0770-000
setmelanotide	Recommendation and Reasons Clinical, Pharmacoeconomic, Ethics, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Dec 12, 2024	Reimbursement Review		Complete	SR0769-000
evolocumab	Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group Input	Dec 11, 2024	Reimbursement Review		Complete	SR0821-000
HR positive, HER2 negative breast cancer	Final Report	Dec 10, 2024	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0053-000
etrasimod	Recommendation and Reason Patient and Clinician Group Input Clinical and Pharmacoeconomic Combined Report Stakeholder feedback on Draft Recommendation	Dec 9, 2024	Reimbursement Review		Complete	SR0795-000
naloxagol	Proposed Scope	Dec 9, 2024	Reimbursement Review		Active	SX0753-000
Use of Oral Fluoroquinolones in Canada: Drug Utilization Study Update	Report Protocol Summary Report	Dec 6, 2024	Health Technology Review	Technology Review	Complete	HC0073-000
Non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutation	Final Report	Dec 5, 2024	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0054-000
Artificial Intelligence–Assisted Colonoscopy for Detecting Polyps, Adenomas, Precancerous Lesions, and Colorectal Cancer	Artificial Intelligence–Assisted Colonoscopy for Detecting Polyps, Adenomas, Pr…	Dec 5, 2024	Health Technology Review	Rapid Review	Completed	RC1559-000
RapidAI for Stroke Detection	Final Recommendation RapidAI for Stroke Detection: Main Report Supporting Information for RapidAI Review Supporting Information for AI Implementation Review	Dec 5, 2024	Health Technology Review	Optimal Use	Active	OP0556-000

Provisional Funding Algorithm

Displaying 76 - 81 of 81